Bioengineering and specialized therapies yield results for rare, challenging blood diseases

In four studies being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, researchers announce promising findings on innovative tools and therapies for hard-to-treat blood disorders including sickle cell disease (SCD), beta thalassemia, and X-linked severe combined immunodeficiency (X-SCID). The studies employ unique therapeutic approaches and advanced engineering technologies such as the gene-editing platform CRISPR/Cas9, reflecting...

What feeling does this article give you?
Joy
Disgust
Fear
Anger
Sadness

#hashtags to follow:

American Society of Hematology [+]    Annual Meeting and Exposition [+]    Atlanta [+]    SCD [+]    SCID [+]    CRISPR [+]   

More #news: